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Mutations in TBK1 have been linked to amyotrophic lateral sclerosis (ALS). Some TBK1 variants are 
nonsense and are predicted to cause disease through haploinsufficiency, however many other mutations are 
missense with unknown functional effect. We exome sequenced 699 familial ALS patients and identified 16 
TBK1 novel or extremely rare protein changing variants. We characterised a subset of these: p.G217R, 
p.R357X and p.C471Y. Here we show that the p.R357X and p.G217R both abolish the ability of TBK1 to 
phosphorylate two of its kinase targets, IRF3 and OPTN and to undergo phosphorylation. They both inhibit 
binding to OPTN and the p.G217R, within the TBK1 kinase domain, reduces homodimerisation, essential 
for TBK1 activation and function. Lastly, we show that the proportion TBK1 that is active (phosphorylated) 
is reduced in five lymphoblastoid cell lines derived from patients harbouring heterozygous missense or in-
frame deletion TBK1 mutations. We conclude that missense mutations in functional domains of TBK1 
impair the binding and phosphorylation of its normal targets, implicating a common loss of function 
mechanism, analogous to truncation mutations. 
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Amyotrophic Lateral Sclerosis (ALS) is an adult onset and progressive neurodegenerative disorder that 
targets the upper and lower motor neurons in the brain and spinal cord. Death usually occurs within three to 
five years from the symptom onset and treatment is largely palliative (Morgan and Orrell, 2016). ALS is 
often associated with cognitive changes linked to mild frontotemporal dementia (FTD) (Gijselinck et al., 
2015) and up to 50% of the FTD cases develop signs of motor neuron disease (MND) (van der Zee et al., 
2017). 
Approximately 10% of ALS cases have a familial history of ALS or FTD (fALS, fALS/FTD) (Tiwari et al., 
2005). To date, more than 40 genes have been identified to be associated with ALS through linkage studies, 
Genome Wide Association Studies (GWAS), Whole Exome Sequencing (WES) and Whole Genome 
Sequencing (WGS). Four genes account for over 50% of fALS cases: SOD1, C9ORF72, TARDBP and 
FUS/TLS in population of European ancestry and most other genes are rare, each accounting for ~1% of the 
cases (Taylor et al., 2016). 
Tank Binding Kinase 1 (TBK1, NAK, T2K) codes for a protein kinase involved in many pathways including 
the immune response and autophagy (Weidberg and Elazar, 2011). TBK1 is composed by four domains: a 
kinase domain (KD), responsible for its kinetic activity, an ubiquitin-like domain (ULD), a scaffold 
dimerization domain (SDD) and a C-terminal domain (CTD), involved in TBK1 association with binding 
partners such as optineurin (OPTN), an important autophagy receptor (Tu et al., 2013) (Figure 1). TBK1 
has been shown to homo-dimerise through a central axis formed by the two SDD domains interacting with 
each other (Figure 1c). This structure is stabilised by the ULD and the KD that interact with each other and 
with the SDD axis, forming a globular head that stabilises the whole structure (Tu et al., 2013). The 
interactions between the ULD, the SDD and their linker region are highly hydrophobic and prevent the 
homodimer from being dissociated when carrying out its functions. On the other hand, interactions of the 
KD within this structure are mainly polar (Tu et al., 2013). TBK1 activation has been demonstrated to be a 
multistep process that begins with the Lys-63-linked polyubiquitination, which is required for Ser172 
phosphorylation within the activation loop. This causes a critical change in protein conformation promoting 
the active position of the C-helix in the SDD domain and facilitating the final step of homo-dimerisation, 
essential for mature kinase activity (Ma et al., 2012; Tu et al., 2013).  
Mutations in TBK1 have been recently linked with ALS and FTD by two WES/WGS independent studies 
(Cirulli et al., 2015; Freischmidt et al., 2015). Many ALS-linked TBK1 mutations generate premature stop 
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autophagy (Freischmidt et al., 2016). However, the pathogenicity and mechanism of missense mutations is 
unclear (Freischmidt et al., 2016). Here we describe 16 novel or extremely rare, potentially deleterious 
variants in TBK1, and demonstrate that missense mutations can lead to a loss of TBK1 kinase activity by 
either disrupting homodimer formation, phosphorylation of itself and its targets Optineurin (OPTN) and 
interferon regulatory factor 3 (IRF3), implicating a loss of function pathogenic mechanism. 
2. Material and Methods  
2.1. Patients and DNA samples 
All patients and controls individuals gave full patient consent for research purpose. DNA was extracted 
from 932 patient samples primarily of European ancestry of which 757 were index cases and 175 were 
affected relatives. All patients had a diagnosis of ALS following revised El Escorial criteria (Brooks et al., 
2000) with at least one family member affected by ALS and/or FTD. Any sample positive for mutations in 
known ALS genes (eg. SOD1, C9orf72, TARDBP, FUS, PFN1, UBQLN2, OPTN, VCP, and ANG) were 
excluded from further analysis, resulting in a final cohort of 699 probands. Exome sequence data for 102 
FALS cases in this cohort were obtained, with permission, from the dbGAP (database of Genotypes and 
Phenotypes) repository (National Institutes of Health (NIH) Exome Sequencing of FALS, National Institute 
of Neurological Disorders and Stroke (NINDS), phs000101. v4.p1, Traynor). 
2.2. Exome sequencing and variant analysis 
Exomes were captured from the UK samples using the Roche-Nimblegen SeqCap EZ Exome probe library 
and sequenced on an Illumina HiSeq 2000 producing 100 bp paired-end (PE) reads. All other exomes were 
provided as FASTQ files, captured with a variety of probe sets and sequenced to produce either 50, 75, or 
100 bp Illumina PE reads. Novocraft NovoAlign was used to align the FASTQ files to the hg19 human 
reference, variants were called with SAMtools v1.1mpileup then normalised with bcftools v1.1 norm. 
Individual variant call files (VCF) were filtered by the following criteria: DP≥10, QUAL>20, GQ≥50, and 
MQ≥50 then merged to a single cohort VCF. Common ancestry between samples was taken from existing 
familial annotation where available and also deduced from inheritance by descent (IBD) analysis in vcftools 
(Yang et al., 2011) and King (Manichaikul et al., 2010), using only variant positions covered to a depth >10 
in >85% of FALS cases, and recoding all missing data to a heterozygous reference genotype (0/0). 
Functional annotation, pathogenicity predictions, AdaBoost (ADA) & Random Forest (RF) splicing 
predictions (Jian et al., 2014) and matches to 1000 genomes were added with table_annovar.pl (Wang et al., 
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http://evs.gs.washington.edu/EVS), Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org) 
and UK10K (www.uk10k.org), were added via custom perl scripts. Variants were removed if they had a 
carrier frequency of greater than 1 in 20,000 in the Non-Finnish European (NFE) subset of ExAC 
(MAF>0.0025%) or were predicted benign by at least 15 of the 20 pathogenicity prediction algorithms. 
Synonymous and intronic variants were assessed by NetGene2 and GeneSplicer and excluded if no changes 
in scores were observed compared to the reference allele at locations matching to known Refseq acceptor or 
donor splice sites. 5’ and 3’ UTR variants were excluded from consideration in this analysis. To assess the 
relative abundance of TBK1 variants in our cohort compared to ExAC, a burden test (Fisher’s Exact, two 
tailed) was performed between the number of FALS and ExAC NFE variants remaining after annotation 
and filtering by the above criteria.  
2.3. Plasmid and Cloning 
HA-tagged TBK1 wild type (WT) and FLAG-tagged OPTN pCMV3 expression vectors were purchased 
from Creative Biogene Biotechnology. Single amino acid changes (p.G217R, p.R357X, p.C471Y) were 
introduced in HA-tagged TBK1 WT by site direct mutagenesis using Q5® Site-Directed Mutagenesis Kit 
according to manufacturer’s protocol (New England Biolabs). All constructs were verified by Sanger 
sequencing. 
2.4. Antibodies 
Mouse and rabbit HA-tag monoclonal antibodies were used at a dilution of 1/1000 for western blot and 
1/500 for immunocytochemistry (ICC) (cat no. 2367 and 3724, Cell Signaling Technology). Rabbit anti-
TBK1 monoclonal antibody was used at a dilution of 1/1000 (cat no ab40676, Abcam). Rabbit anti-
phospho-TBK1 (S172) monoclonal antibody was used at a dilution of 1/500 for western blot and 1/50 for 
ICC (cat no. 5483, Cell Signaling Technology). Rabbit anti- Interferon regulatory factor 3 (IRF3) 
polyclonal antibody was used at a dilution of 1/200 (cat no. A022993, Bioassay Technology Laboratory). 
Rabbit anti-phospho-IRF-3 (Ser396) monoclonal antibody was used at a dilution of 1/200 for ICC and 
western blot (Cat no. ab76493, Abcam). Mouse anti- DYKDDDDK (FLAG) monoclonal antibody was used 
at a dilution of 1/3000 (Cat no. TA5001, Origene). Mouse anti- Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) monoclonal antibody was used at a dilution of 1/6000 (Cat no. G8795, Sigma-Aldrich). 
2.5. Culture of lymphoblastoid cell lines 
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European Collection of Authenticated Cell Cultures (ECACC). LCLs were grown in RPMI media (Gibco, 
Life Technologies) complemented with 10% FBS (Fetal Bovine Serum, Life Technolgies), 5% PenStrep 
(penicillin 100 U/ml and streptomicin 100 U/ml, Life Technologies) and 5% L-Glutamine (Life 
Technologies). These cells grow in suspension and were, therefore, kept in upright T25 flasks (Nunc, Life 
Technologies) in a water-jacketed 5% CO2 incubator. 
2.6. Culture and Transfection of HEK293T cells 
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% Foetal Bovine 
Serum (FBS), 5% PenStrep (penicillin 100 U/ml and streptomicin 100 U/ml), 5% Glutamine (Life 
Technologies) in a water-jacketed 5% CO2 incubator. For western blot, native gel and immunoprecipitation 
analysis cells were plated in six-well plates (Life Technologies) and transfected with 1µg of plasmid DNA, 
2 µl of Lipofectamine 2000 (Life Technologies) and 100 µl of OPTIMEM (Life Technologies) per well 
according to manufacturer’s instructions. For immunofluorescence (ICC), HEK293T cells were plated in 24 
well-plates (Life Technologies) on thirteen-mm-diameter coverslips (VWR) pre-coated with poly-D-lysine 
(Sigma-Aldrich) and transfected with 250 ng of plasmid DNA, 0.5 µl of Lipofectamine 2000 (Life 
Technologies) and 25 µl of OPTIMEM (Life Technologies) per well, according to manufacturer’s 
instructions. Cells were processed for western blot, immunoprecipitation, native gel or ICC after 48 hours 
of transient transfection.  
2.7. RNA extraction and RT-PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol. The 
extracted RNA was used as a template for the synthesis of complementary DNA (cDNA) through reverse 
transcription, using SuperScript® III Reverse Transcriptase (Life Technologies) following manufacturer’s 
protocol. Oligo dT were used to synthesise cDNA. cDNA was amplified using the PCR primers 
ATGCAGAGCACTTCTAATCATCTGTGGC and CTAAAGACAGTCAACGTTGCGAAG and Sanger 
sequenced using the sequencing primers TTGAAGGGCCTCGTAGGAAT and 
TCAGCCATCGTATCCCCTTT. 
2.8. Immunocytochemistry (ICC) 
48 hours after transfection cells were fixed with 4% PFA at room temperature for fifteen minutes, 
permeabilised with 0.2% Triton-X-100 for 30 minutes and blocked with 5% Goat Serum (Sigma) for one 
hour at room temperature. Samples were incubated with primary antibody (anti-HA tag 1/500, anti-pTBK1 
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(Alexa Fluor 488 Goat IgG Antibody, Alexa Fluor 568 Goat IgG Antibody, 1/500 Life Technologies) were 
used for fluorescence detection according to manufacturer’s instructions. As a negative control samples 
were incubated with primary antibody only or secondary antibody only (data not shown). DAPI (4’, 6-
diamidino-2-phenylindole) was used to detect the nuclei. Coverslips were mounted on microscope slides 
(Thermo Scientific) and imaged using Leica confocal SP5 microscope (Leica).  
2.9. Western blot analysis 
HEK293T cells were harvested 48 hours after transfection in Phosphate-Buffer Saline (PBS, Severn 
Biotech LTD) complemented with phosphatase inhibitors (PhoSTOP, Roche) and proteinase inhibitors 
(COMPLETE, Roche). LCLs were harvested collecting cells in 15ml tube (Falcon), centrifuged to form a 
pellet and resuspended in PBS complemented with phosphatase inhibitors (PhoSTOP, Roche) and 
proteinase inhibitors (COMPLETE, Roche). Cells were then lysed and processed as previously described 
(Scotter et al., 2014). Membrane imaging was conducted using goat anti-rabbit, and anti-mouse IgG (H+L) 
DyLight 680 Conjugate (cat. no. 35568 and 35521, Thermo Life Sciences) and a LI-COR Odyssey or using 
horseradish peroxidase (HRP) secondary antibodies for mouse (Millipore, 12-349) or rabbit (Millipore, 12-
348) and developed through Enhanced chemiluminescence (ECL) system using Medical Film Processor 
SRX-101A (Konica Minolta). Western blot quantification was performed using the image analysis 
software, ImageJ (http://imagej.nih.gov/ij/ (Schindelin et al., 2012)). 
2.10. Native gel electrophoresis 
Cells were harvested in PBS complemented with phosphatase inhibitors and proteinase inhibitors. Samples 
were then processed using NativePAGE™ Novex® Bis-Tris Gel System according to manufacturer’s 
protocol. Protein were transferred on a polyvinylidene difluoride (PVDF) membrane, previously activated 
in methanol, using wet transfer system (300mA one hour). The membrane was then incubated in 8% acetic 
acid, air dried and washed in methanol. A blocking solution of 5% bovine serum albumin (BSA) was used 
to block the membrane for 30 minutes prior incubation with 1% BSA and primary antibody (anti-HA tag 
1/200) at 4°C overnight. Membrane imaging was conducted using goat anti-rabbit, and anti-mouse IgG 
(H+L) DyLight 680 Conjugate (cat. no. 35568 and 35521, Thermo Life Sciences) and a LI-COR Odyssey.  
2.11. Cotransfection IP assay  
Cells were transfected with TBK1 WT and mutant plasmids together with OPTN WT plasmids. Additional 
controls untransfected, and transfected with either TBK1 WT or OPTN WT only were used. After 48 hours 
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100, and 100 mMCaCl2 with protease and phosphatase inhibitors). Lysates were partly harvested and 
diluted in loading buffer complemented with 250 mM 1,4-Dithiothreitol (DTT, Thermo Scientific). The 
lysates were pre cleaned through incubation with Dynabeads ® Protein G for Immunoprecipitation (Life 
Technologies) at 4°C for two hours. The beads were then discarded and the lysate incubated with 
Dynabeads ® Protein G and anti-HA tag antibody (1/100) at room temperature for two hours. As an 
additional negative control two samples transfected with OPTN WT only or TBK1 WT only were incubated 
with beads and no antibody, to reveal any unspecific binding. The beads were separated from the flow-
through (FT) through magnetic separation and washed with IP buffer six times before elution in loading 
buffer complemented with DTT. Lysates and IP fractions were analysed by western blot.  
2.12. Phosphatase assay 
Cells were transfected with TBK1 WT and mutant plasmids together with OPTN WT plasmids. Additional 
controls untransfected or transfected with either TBK1 WT or OPTN WT only were used. After 48 hour 
transfected cells were harvested in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate with protease inhibitor) and sonicated for ten seconds. 
Six µg of protein per sample was added to 3µl of CIP buffer (100 mM NaCl, 50 mM Tris-HCl, 10 mM 
MgCl2, 1 mM dithiothreitol, pH to 7.9 at 25°C) and 3µl of alkaline phosphatase (Roche) were added to the 
phosphatase positive samples, according to Abcam protein dephosphorylation protocol 
(http://www.abcam.com/protocols/protein-dephosphorylation-protocol). All the samples were incubated for 
30 minutes at 37 °C and ran on NuPAGE Novex 3-8% Tris-Acetate Midi Protein Gels (Life Technologies). 
Membrane imaging was conducted with fluorescent secondary antibodies and a LI-COR Odyssey.  
2.13. Statistical Analysis 
Statistical analysis of western blot data was performed using GraphPadPrism software. One way ANOVA 
analysis followed by Dunnett’s post-test was applied to datasets. A t-test was used to compare the mean of 
two groups of data. T tests were unpaired, two tailed with 95% confidence intervals. 
3. Results 
3.1. Exome Sequencing in familial ALS detects 16 protein-changing TBK1 variants 
We exome sequenced 699 index cases from a cohort of fALS from eleven countries, negative for mutations 
in all known ALS genes (including SOD1, TDP43, C9ORF72, FUS, PFN1, UBQLN2, OPTN, VCP, and 
ANG), and the intronic C9ORF72 repeat expansion. 
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ExAC Non-Finnish European (NFE) carrier frequency of <1:20,000 individuals. A similar filtering strategy 
applied to the NFE subset of ExAC identified 54 variants from a total of 33,075 individuals, revealing a 
significant overabundance of protein-changing TBK1 variants in our familiar cohort (p=1.02e-10, Fisher’s 
two-tailed test). Thirteen of these variants were absent from the following databases: 1000 genomes, 
UK10K, Exome Variant Server (EVS), and ExAC databases (n > 72,000). Two variants (p.R357Q, 
p.C471Y) were found once and one variant (p.R358H) was found seven times. Out of the 16 variants 
identified: four were nonsense, three in-frame deletion and nine were missense variants (Supplementary 
table 1). The p.G217R variant is present in two Dutch cases predicted to be first degree relatives (King 
kinship coefficient=0.314, vcftools Ajk=0.451), and is their only shared novel variant in a gene or pathway 
previously linked to ALS. The variant p.R357X is also present in a single FALS case in the ALS data 
browser (ALSdb) however, this is unlikely to be closely related to the p.R357X carrier identified in this 
study as they lack any other shared rare variants. Amongst the previously excluded FALS samples, another 
novel missense variant (p.Y394D) was identified in a patient who harbours the known pathogenic TARDP 
mutation, p.M337V, which segregated in their affected sibling. However, the available exome data did not 
have sufficient coverage to determine if the sibling also shared the TBK1 variant and DNA was not 
available to determine segregation by Sanger sequencing. Furthermore, the TBK1 variant p.R358H was 
present in both 1st-degree relatives of a kindred, but both were also carriers for the particularly aggressive 
FUS p.R521C mutation.  
By mapping TBK1 missense separately from nonsense variants we observed difference in their distribution 
(Figure1A,B). Whilst nonsense variants were spread across the whole protein, missense variants tended to 
cluster within the kinase domain (KD) and ubiquitin-like domain (ULD). Interestingly, the ULD has been 
reported to interact with both the scaffold dimerization domain (SDD) and the KD. These interactions play 
a vital role in the correct folding and dimerization of TBK1 (Li et al., 2012; Tu et al., 2013). 
3.2. Selection of variants likely to be pathogenic  
To focus our functional characterisation of TBK1 variants identified in our cohort, we concentrated on three 
variants. We firstly chose the missense p.G217R variant as two related individuals carried this mutation and 
only one TBK1 missense mutation had previously been shown to segregate with disease (van der Zee et al., 
2017). The second nonsense variant p.R357X was selected as it was present in ALSdb. Three variants 
(p.G217R, p.R357X and p.C471Y) all scored highly using algorithms that predicted the variant to be 
damaging, and they appeared to be within functional domains according to the TBK1 homodimer crystal 
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predicted to be damaging by 17/20 of applied algorithms. The p.R357X mutation is located in the ULD and 
found to remove the entire SDD. The p.C471Y is located in the SDD and may therefore impair TBK1 
homodimerisation (Figure 1 A,B).  
3.3. ALS-linked TBK1 variants decrease the phosphorylation of the TBK1 target IRF3 
Some ALS and FTD associated TBK1 variants have previously been shown to diminish or abolish 
phosphorylation of the TBK1 target IRF3 (Freischmidt et al., 2015; Kim et al., 2016; Pozzi et al., 2017; 
Tsai et al., 2016). In order to test the efficiency of p.G217R, p.R357X and p.C471Y on IRF3 
phosphorylation, we transiently transfected HEK293T cells with wild-type (WT) or mutant TBK1 and 
quantified IRF3 phosphorylation by Western blot. The expression levels of total IRF3 were comparable for 
WT and mutant constructs (Figure 2A,B), however, levels of phospho-IRF3 (pIRF3) were significantly 
reduced in p.G217R and p.R357X variant compared to the WT by western blot (Figure 2A,B) and 
immunocytochemistry (Figure 2D). Interestingly, the p.C471Y variant, predicted to be pathogenic by our 
bioinformatic tools, showed no difference from WT. Thus, both missense p.G217R and nonsense p.R357X 
mutations, but not the p.C471Y variant, abolished TBK1 kinase activity on its target IRF3. 
3.4. ALS-linked TBK1 variants decrease binding to OPTN and its phosphorylation 
TBK1 is known to phosphorylate and regulate the activity of OPTN, a key receptor for poly-ubiquitinated 
proteins and mitochondria in autophagy pathways (Richter et al., 2016). TBK1 binds to the N-terminal 
region of OPTN (26–119) , via its C-terminal domain (residues 677–729) (Li et al., 2016) and 
phosphorylates it on Ser177 (Wild et al., 2011) and Ser473 (Heo et al., 2015; Richter et al., 2016). Since 
mutations in OPTN are also linked to ALS, we tested whether our ALS-associated TBK1 variants affected 
its ability to bind to OPTN and phosphorylate it. Co-immunoprecipitation (Co-IP) of HA tagged WT and 
p.C471Y TBK1 consistently pulled down flag tagged OPTN (Figure 2C), however, p.G217R and p.R357X 
dramatically reduced TBK1 binding to OPTN. This finding was validated by the observation that the same 
two mutants also failed to phosphorylate OPTN. While TBK1 WT and p.C471Y generated a higher band on 
western blot that disappeared in the presence of alkaline phosphatase, the higher band is absent following 
co-transfection with OPTN WT and TBK1 p.G217R or p.R357X (Figure 2E). We conclude that both 
missense p.G217R and nonsense p.R357X mutations, but not p.C471Y, impair TBK1 binding to and 
phosphorylation of OPTN. 
3.5. ALS-linked TBK1 variants decrease the phosphorylation of TBK1 
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promoting the active position of the C helix (Tu et al., 2013). We therefore tested whether the ALS-
associated TBK1 variants affect the phosphorylation and autophosphorylation of TBK1 itself. Western blots 
of HEK293T cells, transfected with each variant, were probed with an antibody specific for phospho-S172. 
Total TBK1 expression was similar for WT and all of the ALS-associated variants (Figure 3A,C). Robust 
levels of phospho-S172 TBK1 were evident in WT and p.C471Y transfected cells but were absent in cells 
expressing p.G217R and p.R357X (Figure 3A,B). Similarly, transfected HEK293T cells stained for 
phopsho-S172 TBK1 by immunocytochemistry confirmed that TBK1 phosphorylation was absent in cells 
expressing p.G217R and p.R357X mutants (Figure 3E). This indicates that the missense p.G217R and 
nonsense p.R357X but not the p.C471Y variant abolished the capacity of TBK1 for autophosphorylation. 
3.6. ALS-linked variant p.G217R disrupts TBK1 homodimerisation 
TBK1 has to homodimerise in order to be functional and does so via a central axis formed by aligning the 
two SDD domains in a parallel orientation. The ULD and KD domains interact with each other at one end 
of the dimer creating a globular structure and stabilising the homodimer (Tu et al., 2013) (Figure1C). We, 
therefore, investigated whether any of our variants affected the homodimerisation of TBK1 by transfecting 
HEK293T cells with TBK1 WT, p.G217R, p.R357X and p.C471Y and ran the lysates on non-denaturing 
gels (Figure 3B). Native blots revealed two strong high and low molecular weight bands for WT and 
p.C471Y TBK1, indicating that a similar proportion exists as a homodimer and monomer. Little 
dimerization, however, was evident for the p.G217R mutant and no band was visible for the p.R357X 
truncation mutant (Figure 3B,D). Quantification of the dimer/monomer ratio confirmed that the missense 
p.G217R kinase domain mutation showed a significantly lower TBK1 homodimerisation compared to WT 
(p<0.05) (Figure 3D). 
3.7. TBK1 phosphorylation in ALS patient lymphoblastoid cell lines 
In order to assess whether TBK1 activation is altered in ALS we measured total TBK1 and phospho-TBK1 
in patient lymphoblastoid cell lines (LCLs) heterozygous for TBK1 variants: p.T31A, c.992+1G>A 
(p.G272-T331del), p.R358H, p.Q565P, p.E643del and seven control LCLs. Firstly we sought to determine 
whether the c.992+1G>A causes an in-frame deletion of exon 8 within the ubiquitin-like domain. cDNA 
was amplified by PCR from the patient derived LCL harbouring the c.992+1G>A variant using primers 
flanking the whole of TBK1 and run an agarose gel (Supplementary Figure 1). We observed a lower band 
reflecting a ~200bp deletion, corresponding to the size of exon 8 and similar to the previously reported 
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The skipping of exon 8 was confirmed by Sanger sequencing. 
Quantification of western blots confirmed that total TBK1 was expressed at a similar level in all of the 
LCLs. Probing the same blots for phospho-S172-TBK1 revealed that the ratio between pTBK1 and total 
TBK1 is significantly different between patient and control derived LCLs (p=0.0229, Figure 4). Therefore, 
missense TBK1 mutations lead to reduced phosphorylation by self-interaction or with other kinases. 
4. Discussion  
In this study, we systematically analysed samples from 699 index fALS patients and identified 16 TBK1 
variants including 4 nonsense mutations, predicted to cause haploinsufficiency by nonsense mediated RNA 
decay or to be translated as truncated proteins. Three were in frame deletions and nine missense, which 
appear to cluster in the functional kinase and ubiquitin like domains known to play a role in TBK1 
homodimerisation (Li et al., 2012; Tu et al., 2013). Five of these variants have never been published before: 
p.M623fs, p.Q629fs, p.T31A, p.R358H and c.992+1G>A (predicted to splice out the whole of exon 8 
resulting in an in frame deletion within the ULD). The c.992+1G>A variant was reported once in ALSdb. 
Of the other variants only p.R357Q, p.E643del and p.T79del have been functionally investigated 
(Freischmidt et al., 2015; Gijselinck et al., 2015; van der Zee et al., 2017). Interestingly, disease onset in the 
patient harbouring both the TBK1 p.Y394D and TARDP p.M337V mutations was 40 years (Table 1), which 
is 20 years earlier than the average age of onset described in literature (Pozzi et al., 2017). This double hit 
phenomenon was also described by Freischmidt and colleagues in the patients (all three affected relatives) 
harbouring TBK1 p.Y185X and FUS p.R524G (Freischmidt et al., 2015). 
We characterised the functional impact of three ALS-linked variants selected on the basis of their predicted 
disruption to key functional domains within TBK1 (Figure 1C). We chose p.G217R as it lies within the KD 
and was found in a putative affected sibling, p.R357X as it lies within the ULD and was found in an 
unrelated case in ALSdb and p.C471Y, which lies within the SDD. Only p.G217R and p.R357X TBK1 
variants, but not p.C471Y, abolished the phosphorylation of IRF3. This has previously been described for 
other ALS-associated mutations (Freischmidt et al., 2015; Kim et al., 2016; Tsai et al., 2016). The same 
TBK1 variants, p.G217R and p.R357X, also abolished TBK1 binding to OPTN and prevented its 
phosphorylation. The inhibition of TBK1 binding to OPTN has been previously observed in ALS linked 
TBK1 variants, mainly located in the C-terminal region of the protein (Freischmidt et al., 2015; Kim et al., 
2016; Pozzi et al., 2017; Tsai et al., 2016). However, the inhibition OPTN phosphorylation due to TBK1 
mutations has never been shown before. A reduction in active OPTN phosphorylation would impair its 
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been observed in patients harbouring TBK1 mutations (Gijselinck et al., 2015; Pottier et al., 2015; van der 
Zee et al., 2017). 
To become activated TBK1 must form a homodimer and be phosphorylated either by itself or by other 
kinases (Tu et al., 2013). Here we show that the p.G217R and p.R357X variants impair TBK1 
autophosphorylation and its ability to be phosphorylated. This observation is consistent with a recent study 
that showed diminished TBK1 phosphorylation in ALS-associated TBK1 in-frame deletions (p.T79del, 
p.D167del, p.E643del) (van der Zee et al., 2017). We have also shown that p.G217R, although located in 
the KD, affects TBK1 ability to homodimerise. In contrast, the p.C471Y variant within the SDD is able to 
phosphorylate and homodimerise at equivalent levels to the wildtype TBK1 protein and shows no evidence 
of pathogenicity.  
Lastly, we demonstrated that there is a significant difference between phospho-TBK1 and total TBK1 ratio 
in patient compared to control derived LCLs. This supports the hypothesis that disease-linked TBK1 
variants might impair TBK1 autophosphorylation, disrupting its ability to bind and phosphorylate multiple 
partners including OPTN. 
5. Conclusions 
We have identified four novel and 12 previously described TBK1 variants in ALS patients. Our functional 
studies demonstrated that the missense mutation p.G217R in the KD has an almost identical profile as the 
truncation p.R357X in the ULD, and dramatically impairs the ability of TBK1 to form homodimers, auto-
phosphorylate and function as a kinase. Furthermore, the proportion of TBK1 that is activated is 
significantly reduces in five lymphoblast ALS patient lines carrying missense or in-frame deletion 
mutations. Thus, missense mutations in critical functional domains may cause disease through a loss of 
TBK1 function supporting functional haploinsufficiency as a common TBK1 disease mechanism (Cirulli et 
al., 2015; Freischmidt et al., 2016, 2015). Further investigation of how ALS-linked TBK1 variants alter 
TBK1 structure, phosphorylation and dimerisation will help unravel the disease pathogenesis and identify 
novel therapeutic targets.  
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10. Figure legends 
Figure 1. TBK1 mutations identified to date and their location in TBK1 structure. (A,B) Schematic 
representation of TBK1 protein structure (Tu et al., 2013) showing a map of nonsense (A) and missense (B) 
variants found in literature and in our cohort. For more details on the variants found in this study see 
Supplementary table 1. (KD = Kinase domain (pink), ULD = Ubiquitin like domain (purple), SDD = 
Scaffold dimerization domain CTD = C-terminal domain (green)). (C) TBK1 homodimer crystal structure 
(PDB 4IM0) mapping the mutations found in our study excluding premature stop codons and frameshift 
deletions. 
 
Figure 2. TBK1 p.G217R and p.R357X impair IRF3 phosphorylation as well as TBK1 binding with 
OPTN and its phosphorylation. (A) Western blot analysis of IRF3 (left) and pIRF3 (right). (B left) 
Quantitative analysis of blot in (A) left showing a similar expression level of endogenous IRF3 in cells 
(n=3). (B right) Quantitative analysis of blot in (A) right showing a significant decrease of expression of 
endogenous pIRF3 in cells transfected with TBK1-p.G217R and p.R357X (n=3, analysed by One Way 
ANOVA followed by Dunnett’s post test p<0.0001). (C) Qualitative immunocytochemistry of HEK293T 
transfected with TBK1-WT, p.G217R, p.R357X and probed for p-IRF3 confirming the result obtained by 
western blot analysis (scale bar = 50 µm). (D) Co-IP with HA-tag pull down (TBK1) showing no biding of 
OPTN in any of the mutated samples with the exception of p.C471Y (n=3). (E) HEK293T were transiently 
co-transfected with Flag-OPTN WT and HA-TBK1 WT, p.G217R, p.R357X or p.C471Y, treated with 
alkaline phosphatase and analysed by western blot showing lack of OPTN phosphorylation in all mutated 
samples a part from p.C471Y. 
 
Figure 3. TBK1 p.G217R and p.R357X impair TBK1 phosphorylation and auto phosphorylation and 
might reduce TBK1 homodimerisation.  (A) Western blot analysis of TBK1 expression levels (left) and 
pTBK1 (right) (B left) Quantitative analysis of blot in (A) left showing a similar expression level of TBK1 
in cells (n=4).  (B right) Quantitative analysis of blot in (A) right showing a significant decrease of 
expression of pTBK1 in p.G217R and p.R357X (n=4 analysed by One Way ANOVA followed by 
Dunnett’s post test p<0.0001). (C) Immunocytochemistry of HEK293T transfected with TBK1-WT, 
p.G217R, p.R357X and probed for p-TBK1 confirming the result obtained by western blot analysis (Figure 
3) (Scale bar = 10 µm). (D) Native gel showing dimer and monomer (indicated by black arrows) in TBK1-
WT and TBK1-C471Y, weaker dimer and monomer in p.G217R sample and no dimer or monomer in 
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ACCEPTED MANUSCRIPTR357X sample. (E) Quantitative analysis of gel in (D) showing significant reduction in dimer formation for 
p.G217R (positive control on the right TBK1 WT treated with DTT, n=3, analysed by One Way ANOVA 
followed by Dunnett’s post test p<0.05). 
 
Figure 4. Patient-derived LCLs harbouring TBK1 variants show reduced level of TBK1 
phosphorylation. (A top) Western blot of control and patient-derived LCLs, harbouring five different 
TBK1 variants, showing the level of total TBK1 (A bottom) Western blot showing phopsho-TBK1 
expression in patient and control derived lymphoblasts. (B) Dot plot showing a significant difference the 
ratio of phospho-TBK1 and total TBK1 between control and patient derived LCLs (analysed by unpaired t-
test, two tailed p=0.0229). 
 
Supplementary figure 1. TBK1 variant c.992+1G>A produces the in-frame deletion of exon 8.  
Agarose gel on cDNA extracted from WT and c.992+1G<A (p.G272-T331 del) LCLs showing two 
different sized bands for the WT allele and the mutated allele carrying c.992+1 G>A compared to the 
sample carrying both WT alleles (WT/C992+1G>A WT allele: 2190 bp, WT/C992+1G>A mutated allele: 
1990bp, WT/WT: 2190bp). The boxes above and below show the sequencing of the WT/WT sample and 
the sequencing of the WT/c.992+1G>A sample, respectively. 
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Type Of 
Variant Exon Nucleotide Variation
a
 Residue Change Number 
of cases 
Control 
Frequency Gender 
Clinical 
Diagnosis 
Site of 
Onset 
Age of 
Onset 
(years) 
Disease 
duration 
(months) 
Reference 
Nonsense 
Variants 
2 c.4C>T p.Gln2Ter 1 0/82,513 F ALS S 60 - (Cirulli et al. 2015; Gijselinck et al. 2015) 
9 c.1069C>T p.Arg357Ter 1{1} 0/82,519 F ALS UL 76 - (Cirulli et al. 2015) 
18 c.1869_1875del p.Met623IlefsdTer9 1 0/82,359 F ALS - 43 20.4 - 
18 c.1887_1890del p.Gln629HisfsTer4 1 0/82,445 F ALS - - - - 
In Frame 
Deletions 
4 c.236_238delCAA p.Thr79del 1 0/82,314 M ALS R 67.8 7.3 (van der Zee et al., 2016) 
- 992+1 G>A p.Gly272_Thr331del 1{1} 0/80,635 M ALS - 46 24 - 
18 c.1928_1930delAAG p.Glu643del 1{1} 0/82,323 M ALS UL 64 48 (Cirulli et al. 2015; Freischmidt et al. 2015; Gijselinck et al. 2015; van der Zee et al. 2016) 
Missense 
Variants 
2 c.64A>C p.Asn22His 1{1} 0/82,490 F ALS - 49 12 (Cirulli et al. 2015) 
2 c.92A>G p.Thr31Ala 1 0/80,639 M ALS - - - - 
5 c.385A>G p.Asn129Asp 1 0/82599 M ALS L 68 - (Cirulli et al. 2015) 
6 c.649G>A p.Gly217Arg 1 (1*) 0/82,595 M,M ALS - - - (Cirulli et al. 2015) 
9 c.1070G>A p.Arg357Gln 1 {1} 1/82,519 M ALS LL 50 94 (Freischmidt et al., 2015; Pozzi et al., 2017) 
9 c.1073G>A p.Arg358His 1(1*) 7/82519 - - - - - - 
9 c.1180T>G p.Tyr394Asp 1{1#} 0/82,080 F ALS B 40 - (Cirulli et al. 2015) 
12 c.1412G>A p.Cys471Tyr 1 1/79,400 F ALS - - - (Cirulli et al. 2015) 
15 c.1694A>C p.Gln565Pro 1 {1} 0/75,603 F ALS UL 50 36 (Cirulli et al. 2015) 
Table 1 – TBK1 mutations identified in ALS patients by this study and their clinical phenotype. a 
Mutation nomenclature as recommended by the Human Genome Variation society www.hgvs.org, utilising 
+1 as the A of the initiator Met codon, translation start site. (*) affected relative from the present cohort. 
Cases number=699. The number in brackets ({}) represent the cases reported in ALSdb 
(http://alsdb.org/index.jsp). {#} represents duplicated sample found in ALSdb. S=spinal, UL=Upper Limb, 
R=respiratory, L=limb, LL=Lower Limb, B=bulbar. 
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12. Abbreviation list 
 
ALS Amyotrophic Lateral Sclerosis 
ALSdb Amyotrophic Lateral Sclerosis data base 
ANG Angiogenin 
C9ORF72 Chromosome 9 Open Reading Frame 72 
CTD C-terminal domain 
EVS Exome Variant Server  
ExAC Exome Aggregation Consortium 
fALS  Familial Amyotrophic Lateral Sclerosis 
FTD Frontotemporal Dementia 
FUS Fused in Sarcoma  
GWAS Genome Wide Association Studies 
IRF3 Interferon Regulatory Factor 3 
JPND Joint Programme – Neurodegenerative Disease Research 
KD Kinase Domain 
LCL Lymphoblastoid Cell Lines 
MND Motor Neurone Disease 
NFE Non-Finnish European 
OPTN Optineurin 
PDB Protein Data Bank 
PFN1 Profilin 1 
SDD Scaffold Dimerisation Domain 
SOD1 Superoxide Dismutase 1 
TBK1 Tank Binding Kinase 1 
TDP43 TAR DNA-binding protein 43 
UBQLN2 Ubiquilin 2 
ULD Ubiquitin-Like Domain  
WES Whole Exome Sequencing 
WGS Whole Genome Sequencing  
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Highlights 
 
• The p.R357X and p.G217R TBK1 mutations both abolish TBK1 ability to phosphorylate two of 
its targets, IRF3 and optineurin (OPTN), to undergo phosphorylation as well as to bind OPTN. 
 
• The proportion of active TBK1 (phosphorylated) is reduced in five lymphoblastoid cell lines 
derived from patients harbouring heterozygous missense or in-frame deletion TBK1 
mutations. 
 
• Missense mutations in TBK1 functional domains impair the binding and phosphorylation of its 
normal targets, implicating a common loss of function mechanism, analogous to truncation 
mutations. 
